Thursday, 15 October 2026European Markets

VÅR ENERGI And DNO Have A High Dividend Yield And Return On Equity In The Oil & Gas E&P Industry.

Loading stream...

(VIANEWS) - VÅR ENERGI (VAR.OL) is among this list of stock assets with the highest dividend rate and return on equity on the Oil & Gas E&P industry.

Financial Asset Price Forward Dividend Yield Return on Equity
VÅR ENERGI (VAR.OL) kr35.76 12.97% 37.56%
DNO (DNO.OL) kr10.31 9.94% 19.33%

Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. VÅR ENERGI (VAR.OL)

12.97% Forward Dividend Yield and 37.56% Return On Equity

Vår Energi AS operates as an independent upstream oil and gas company on the Norwegian continental shelf in Norway. It produces crude oil, liquified natural gas, and natural gas liquids. The company was formerly known as Eni Norge AS and changed its name to Vår Energi AS in December 2018. The company was incorporated in 1965 and is headquartered in Sandnes, Norway. Vår Energi AS operates as a subsidiary of Eni International B.V.

Earnings Per Share

As for profitability, VÅR ENERGI has a trailing twelve months EPS of kr2.23.

PE Ratio

VÅR ENERGI has a trailing twelve months price to earnings ratio of 16.04. Meaning, the purchaser of the share is investing kr16.04 for every norwegian krone of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 37.56%.

Sales Growth

VÅR ENERGI's sales growth is negative 2.6% for the present quarter and 32.1% for the next.

Growth Estimates Quarters

The company's growth estimates for the current quarter and the next is 19.8% and 159.1%, respectively.

More news about VÅR ENERGI.

2. DNO (DNO.OL)

9.94% Forward Dividend Yield and 19.33% Return On Equity

DNO ASA engages in the exploration, development, and production of oil and gas assets in the Middle East, the North Sea, and West Africa. The company holds 75% operating interests in the Tawke and Peshkabir fields, and 64% operating interests in the e Baeshiqa license located in the Kurdistan region of Iraq; has production licenses across 10 fields Norway and two fields in the United Kingdom; and operating interests in the producing Block CI-27, as well as operates the exploration Block CI-12 in West Africa. DNO ASA was founded in 1971 and is headquartered in Oslo, Norway.

Earnings Per Share

As for profitability, DNO has a trailing twelve months EPS of kr0.22.

PE Ratio

DNO has a trailing twelve months price to earnings ratio of 46.86. Meaning, the purchaser of the share is investing kr46.86 for every norwegian krone of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 19.33%.

Growth Estimates Quarters

The company's growth estimates for the current quarter and the next is a negative 65.6% and a negative 86.7%, respectively.

More news about DNO.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com